[Trends in drug-induced liver injury based on reports of adverse reactions to PMDA in Japan].

Q4 Medicine
Chie Sudo, Keiko Maekawa, Katsunori Segawa, Tadaaki Hanatani, Kimie Sai, Yoshiro Saito
{"title":"[Trends in drug-induced liver injury based on reports of adverse reactions to PMDA in Japan].","authors":"Chie Sudo,&nbsp;Keiko Maekawa,&nbsp;Katsunori Segawa,&nbsp;Tadaaki Hanatani,&nbsp;Kimie Sai,&nbsp;Yoshiro Saito","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Reports on drug-related adverse reactions from manufacturing/distributing pharmaceutical companies or medical institutions/pharmacies are regulated under the Pharmaceutical Affairs Law of Japan, and this system is important for post-marketing safety measures. Although association between the medicine and the adverse event has not been clearly evaluated, and an incidence may be redundantly reported, this information would be useful to roughly grasp the current status of drug-related adverse reactions. In the present study, we analyzed the incidence of drug-induced liver injury by screening the open-source data publicized by the homepage of Pharmaceutical and Medical Devices Agency from 2005 to 2011 fiscal years. Major drug-classes suspected to cause general drug-induced liver injury were antineoplastics, anti-inflammatory agents/common cold drugs, chemotherapeutics including antituberculous drugs, antidiabetics, antiulcers and antiepileptics. In addition, reported cases for fulminant hepatitis were also summarized. We found that antituberculous isoniazid and antineoplastic tegafur-uracil were the top two suspected drugs. These results might deepen understanding of current situations for the drug-induced liver injury in Japan.</p>","PeriodicalId":35462,"journal":{"name":"Bulletin of National Institute of Health Sciences","volume":" 130","pages":"66-70"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of National Institute of Health Sciences","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Reports on drug-related adverse reactions from manufacturing/distributing pharmaceutical companies or medical institutions/pharmacies are regulated under the Pharmaceutical Affairs Law of Japan, and this system is important for post-marketing safety measures. Although association between the medicine and the adverse event has not been clearly evaluated, and an incidence may be redundantly reported, this information would be useful to roughly grasp the current status of drug-related adverse reactions. In the present study, we analyzed the incidence of drug-induced liver injury by screening the open-source data publicized by the homepage of Pharmaceutical and Medical Devices Agency from 2005 to 2011 fiscal years. Major drug-classes suspected to cause general drug-induced liver injury were antineoplastics, anti-inflammatory agents/common cold drugs, chemotherapeutics including antituberculous drugs, antidiabetics, antiulcers and antiepileptics. In addition, reported cases for fulminant hepatitis were also summarized. We found that antituberculous isoniazid and antineoplastic tegafur-uracil were the top two suspected drugs. These results might deepen understanding of current situations for the drug-induced liver injury in Japan.

[基于日本PMDA不良反应报告的药物性肝损伤趋势]。
生产/分销制药公司或医疗机构/药房的药物相关不良反应报告受日本《药事法》监管,这一制度对于上市后的安全措施非常重要。虽然药物与不良反应之间的关系尚未得到明确的评估,并且可能有重复的发生率报告,但这些信息将有助于大致掌握药物相关不良反应的现状。本研究通过筛选美国药品和医疗器械管理局(Pharmaceutical and Medical Devices Agency)网站2005 - 2011财年公开的开源数据,对药物性肝损伤的发生率进行分析。怀疑引起一般药物性肝损伤的主要药物类别为抗肿瘤药、抗炎药/普通感冒药、化疗药物(包括抗结核药、抗糖尿病药、抗溃疡药和抗癫痫药)。此外,还对报道的暴发性肝炎病例进行了总结。我们发现抗结核异烟肼和抗肿瘤替加福-尿嘧啶是前两种可疑药物。这些结果可能加深对日本药物性肝损伤现状的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信